Ads
related to: brca2 mutation database
Search results
Results from the WOW.Com Content Network
The BRCA2 gene was discovered in 1994. [35] [16] [36] In 1996, Kenneth Offit and his research group at Memorial Sloan Kettering Cancer Center successfully identified the most common mutation on the gene associated with breast and ovarian cancer among individuals of Ashkenazi Jewish ancestry.
Harmful mutations in BRCA2 - a gene responsible for repairing damaged DNA - significantly increase the risk of breast, ovarian, prostate and pancreatic cancers. About 45% of women who inherit a ...
Inheriting one BRCA1 mutation and one BRCA2 mutation has been reported occasionally; the child's risk for any given type of cancer is the higher risk of the two genes (e.g., the ovarian cancer risk from BRCA1 and the pancreatic cancer risk from BRCA2). Inheriting two BRCA2 mutations produces Fanconi anemia. [9]: 82–85
HRDetect was tested in 80 breast cancer cases with mainly ER positive and HER2 negative. The tool was able to find ones that exceed HRDetect score 0.7, including one germline BRCA1 mutation carrier, four germline BRCA2 mutation carriers and one somatic BRCA2 mutation carrier. The sensitivity of this tool also reached 86%.
A BRCA2 gene mutation is associated with breast cancer, but it can also raise the risk of other cancers. Woman shares story of her pancreatic cancer diagnosis.
The Cancer Genome Atlas (TCGA) is a project to catalogue the genomic alterations responsible for cancer using genome sequencing and bioinformatics. [1] [2] The overarching goal was to apply high-throughput genome analysis techniques to improve the ability to diagnose, treat, and prevent cancer through a better understanding of the genetic basis of the disease.
Database Institute / Organization Alteration Types Primary Source [t 1] Processed Data [t 2] Organisms Cell lines [t 3] Public Data [t 4] Restricted Data [t 5]; The BioExpress® Oncology Suite from Ocimum Bio Solutions contains gene expression data from primary, metastatic, and benign tumor samples, and normal samples, including matched adjacent controls.
Between 2007 and 2011, Metcalfe received funding to help researchers understand the differences in uptake of cancer prevention options in Canadian women with a BRCA1 or BRCA2 mutation. [4] Through this, Metcalfe became the first to investigate the predictors of contralateral breast cancer in women with a BRCA1 or BRCA2 mutations. [5]
Ads
related to: brca2 mutation database